Details of Disease

General Information of Disease (ID: DISI3CW2)

Disease Name	Benign prostatic hyperplasia
Synonyms	BPH; prostatic hyperplasia, benign; prostate hypertrophy; prostatic hypertrophy; benign prostatic Hypertrophy; benign prostatic hyperplasia; benign prostatic hypertrophy; benign hyperplasia of the prostate; benign prostatic hyperplasia (disease); benign hyperplasia of prostate; benign prostatic hyperplasia - BPH; benign prostate hyperplasia
Disease Class	GA90: Prostate hyperplasia
Definition	A non-cancerous nodular enlargement of the prostate gland. It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements. It is the most common urologic disorder in men, causing blockage of urine flow.
Disease Hierarchy	DISFVG19: Prostate disease DISK4DFB: Hyperplasia DISI3CW2: Benign prostatic hyperplasia
ICD Code	ICD-11 ICD-11: GA90 ICD-10 ICD-10: N40 ICD-9 ICD-9: 600 Expand ICD-11 'GA90 Expand ICD-10 'N40 Expand ICD-9 600
Disease Identifiers	MONDO ID MONDO_0010811 MESH ID D011470 UMLS CUI C1704272 OMIM ID 600082 MedGen ID 312369 HPO ID HP:0008711 SNOMED CT ID 266569009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 11 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alfuzosin	DMZVMKF	Approved	Small molecular drug	[1]
Doxazosin	DM9PLRH	Approved	Small molecular drug	[2]
Dutasteride	DMQ4TJK	Approved	Small molecular drug	[3]
Finasteride	DMWV3TZ	Approved	Small molecular drug	[4]
Prazosin	DMCD9YG	Approved	Small molecular drug	[5]
Serenoa repens extract	DMQY0UW	Approved	NA	[5]
SILODOSIN	DMJSBT6	Approved	Small molecular drug	[6]
Tadalafil	DMJZHT1	Approved	Small molecular drug	[7]
Tamsulosin	DM5QF9V	Approved	Small molecular drug	[8]
Terazosin	DM3JCVS	Approved	Small molecular drug	[9]
Xatral	DMLHOA0	Approved	Small molecular drug	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 Drug(s)

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dutasteride + tamsulosin	DM6P8HU	Phase 3	Combination drug (small molecular drug)	[10]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID30124346-Compound-LDT66	DMJMTNL	Patented	Small molecular drug	[11]
PMID30124346-Compound-LDT8	DM5MUNG	Patented	Small molecular drug	[11]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lonidamine	DMCU5LD	Discontinued in Phase 3	Small molecular drug	[12]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 94 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADCYAP1	TTW4LYC	Limited	Altered Expression	[13]
ADCYAP1R1	TT5OREU	Limited	Biomarker	[13]
CFD	TT8D13I	Limited	Altered Expression	[14]
CGA	TTFC29G	Limited	Altered Expression	[15]
EPHA6	TTFAHWI	Limited	Altered Expression	[16]
HAAO	TTWON83	Limited	Posttranslational Modification	[17]
IMP3	TTEJA2R	Limited	Biomarker	[18]
PCNA	TTLG1PD	Limited	Biomarker	[19]
PDE5A	TTJ0IQB	Limited	Biomarker	[20]
PRL	TTJ2TSA	Limited	Biomarker	[21]
THRB	TTGER3L	Limited	Biomarker	[22]
TRPV6	TTBK14N	Limited	Altered Expression	[23]
TLN1	TTQSMFG	Disputed	Altered Expression	[24]
BCL11A	TTR61MW	moderate	Genetic Variation	[25]
DKK3	TTY2ZV6	moderate	Altered Expression	[26]
FGF7	TTFY134	moderate	Biomarker	[27]
TXNRD3	TTDYFVB	moderate	Biomarker	[28]
VDR	TTK59TV	moderate	Genetic Variation	[29]
ADRA1B	TTBRKXS	Strong	Biomarker	[30]
ADRA1D	TT34BHT	Strong	Biomarker	[30]
AMACR	TTLN1AP	Strong	Altered Expression	[31]
BPI	TTXCSDR	Strong	Genetic Variation	[32]
CCNB1	TT9P6OW	Strong	Biomarker	[33]
CFI	TT6ATLX	Strong	Altered Expression	[34]
CGB3	TTUH273	Strong	Altered Expression	[35]
CHRM2	TTYEG6Q	Strong	Altered Expression	[36]
CHRM3	TTQ13Z5	Strong	Genetic Variation	[37]
CRAT	TTC8M31	Strong	Altered Expression	[38]
CYP11A1	TTSYVO6	Strong	Biomarker	[39]
CYP3A4	TTWP7HQ	Strong	Biomarker	[40]
DUT	TTH6MBO	Strong	Biomarker	[41]
ENPP2	TTSCIM2	Strong	Altered Expression	[42]
GDF15	TT4MXVG	Strong	Altered Expression	[43]
GNRH1	TT0ID4A	Strong	Biomarker	[44]
GNRHR	TT8R70G	Strong	Altered Expression	[45]
GPER1	TTDSB34	Strong	Biomarker	[46]
GSR	TTEP6RV	Strong	Biomarker	[47]
HOXA7	TTMRE4Q	Strong	Altered Expression	[48]
HPN	TT25MVL	Strong	Altered Expression	[49]
HSD17B1	TTIWB6L	Strong	Biomarker	[50]
HSD17B2	TT0PT1R	Strong	Biomarker	[51]
IGFBP5	TTDWEA8	Strong	Biomarker	[52]
IL10RB	TTJTRMK	Strong	Genetic Variation	[53]
IL21R	TTZO9B0	Strong	Biomarker	[54]
ITGA4	TTJMF9P	Strong	Altered Expression	[55]
KDM4C	TTV8CRH	Strong	Altered Expression	[56]
KLB	TTARBVH	Strong	Altered Expression	[57]
KLK2	TTJLNAW	Strong	Biomarker	[58]
KLK4	TT4319X	Strong	Altered Expression	[59]
KLK5	TTULSEW	Strong	Altered Expression	[60]
LAMP2	TTULDG7	Strong	Altered Expression	[61]
LASP1	TTZJA87	Strong	Altered Expression	[62]
LONP1	TTM1VPZ	Strong	Altered Expression	[63]
LTBR	TTFO0PM	Strong	Biomarker	[64]
LYZ	TTAOZBW	Strong	Biomarker	[65]
MAP3K3	TTJZNIG	Strong	Altered Expression	[66]
MAP4K4	TT6NI13	Strong	Biomarker	[66]
MAPK7	TTU6FSC	Strong	Biomarker	[66]
MAZ	TT059DA	Strong	Altered Expression	[67]
MSMB	TTYH1ZK	Strong	Biomarker	[68]
MSR1	TT2TDH9	Strong	Genetic Variation	[69]
NPEPPS	TT371QC	Strong	Altered Expression	[70]
ODC1	TTUMGNO	Strong	Biomarker	[71]
OR51E2	TTZRE3C	Strong	Biomarker	[72]
OXTR	TTSCIUP	Strong	Altered Expression	[73]
P2RX1	TTJW7B3	Strong	Altered Expression	[74]
PGC	TT7K6AD	Strong	Altered Expression	[75]
PIM1	TTTN5QW	Strong	Altered Expression	[76]
PIM2	TT69J2Z	Strong	Altered Expression	[77]
PLD1	TT3T17P	Strong	Altered Expression	[78]
PMS1	TTX1ISF	Strong	Altered Expression	[79]
PSCA	TT9T4AV	Strong	Altered Expression	[80]
RNASEL	TT7V0K4	Strong	Genetic Variation	[69]
SEPTIN6	TTAGE7U	Strong	Biomarker	[81]
SERPINB5	TT1KW50	Strong	Biomarker	[82]
SLC33A1	TTL69WB	Strong	Biomarker	[83]
SLC52A2	TT6TKEN	Strong	Altered Expression	[27]
SLC7A1	TT4S150	Strong	Altered Expression	[38]
SMAD9	TTX8EBV	Strong	Altered Expression	[84]
STEAP1	TT9E64S	Strong	Altered Expression	[85]
STEAP2	TTOXF5J	Strong	Altered Expression	[85]
TGFB3	TTWOMY8	Strong	Altered Expression	[86]
TMPRSS2	TT1GM2Z	Strong	Biomarker	[87]
VEGFB	TTPJQHE	Strong	Altered Expression	[88]
VIPR1	TTCL30I	Strong	Biomarker	[89]
CDC37	TT5SOEU	Definitive	Altered Expression	[90]
CXCR5	TTIW59R	Definitive	Biomarker	[91]
FCGR1A	TTZK4I3	Definitive	Altered Expression	[92]
FGF10	TTNPEFX	Definitive	Biomarker	[93]
KLK7	TTE6GTB	Definitive	Altered Expression	[94]
RCE1	TT2AP5B	Definitive	Altered Expression	[95]
SLC2A9	TTIF3GB	Definitive	Altered Expression	[96]
SSTR1	TTIND6G	Definitive	Altered Expression	[97]
SSTR2	TTZ6T9E	Definitive	Altered Expression	[97]
------------------------------------------------------------------------------------


⏷ Show the Full List of 94 DTT(s)

This Disease Is Related to 5 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP12A	DT5NLZA	moderate	Altered Expression	[98]
KCNK2	DTENHUP	Strong	Altered Expression	[99]
SLC18A1	DTM953D	Strong	Biomarker	[100]
SLC25A21	DT2UQYR	Strong	Biomarker	[71]
SLC2A6	DTS4MKQ	Definitive	Altered Expression	[96]
------------------------------------------------------------------------------------

This Disease Is Related to 13 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GCLC	DESYL1F	moderate	Genetic Variation	[101]
CYP3A43	DEO1IE3	Strong	Genetic Variation	[69]
GGCT	DEKW6PB	Strong	Genetic Variation	[102]
HSD17B3	DEX8J7E	Strong	Biomarker	[50]
HSD17B7	DEDMWFX	Strong	Altered Expression	[103]
PSAT1	DEBS17P	Strong	Altered Expression	[70]
UGT1A10	DEL5N6Y	Strong	Genetic Variation	[104]
UGT1A4	DELOY3P	Strong	Genetic Variation	[104]
UGT1A6	DESD26P	Strong	Genetic Variation	[104]
UGT1A7	DEZO4N3	Strong	Genetic Variation	[104]
UGT1A8	DE2GB8N	Strong	Genetic Variation	[104]
UGT2B15	DENZ6B1	Strong	Genetic Variation	[105]
UGT2B17	DEAZDL8	Strong	Genetic Variation	[105]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 DME(s)

This Disease Is Related to 156 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ALOX15B	OTWQQ08W	Limited	Biomarker	[106]
ARIH1	OTO3XDR2	Limited	Biomarker	[107]
CCL19	OTQ2UJMH	Limited	Biomarker	[108]
DLEC1	OTMKKBUW	Limited	Altered Expression	[109]
GADD45GIP1	OT4IZ4TP	Limited	Biomarker	[110]
HOXD3	OTBUZ35T	Limited	Biomarker	[17]
SMURF2	OT3TRVL7	Limited	Altered Expression	[111]
SPINT1	OT1CLR5L	Limited	Altered Expression	[112]
TDRD1	OT0CBCI3	Limited	Biomarker	[17]
C17orf49	OTKPULAA	Disputed	Altered Expression	[113]
BET1L	OT5QVYBZ	moderate	Genetic Variation	[25]
CLPTM1L	OTDJWQXI	moderate	Genetic Variation	[25]
CREBRF	OT2GK1HI	moderate	Altered Expression	[114]
ELOVL6	OTB26UJJ	moderate	Genetic Variation	[101]
GATA5	OTO81B63	moderate	Genetic Variation	[25]
HEY2	OTU4J3ZI	moderate	Biomarker	[115]
HNF1B	OTSYIC3T	moderate	Genetic Variation	[25]
LILRA3	OTBNQCOS	moderate	Biomarker	[116]
NRBP1	OTRWEJ65	moderate	Altered Expression	[117]
SWAP70	OTPHT2QD	moderate	Biomarker	[118]
SYN3	OTSGYNA5	moderate	Genetic Variation	[101]
TBX3	OTM64N7K	moderate	Genetic Variation	[25]
TM4SF1	OTY0ECQN	moderate	Altered Expression	[119]
AFAP1	OTR473H8	Strong	Altered Expression	[120]
AKAP12	OTCVRDDX	Strong	Posttranslational Modification	[121]
ALDH7A1	OTV57BZD	Strong	Biomarker	[122]
ALKBH3	OTS1CD9Z	Strong	Altered Expression	[123]
ANKS4B	OT1MREUS	Strong	Biomarker	[124]
AP3B1	OTYTIH5Q	Strong	Altered Expression	[125]
ARF6	OTVV7KJO	Strong	Altered Expression	[126]
ARL11	OTF6UDDB	Strong	Altered Expression	[127]
ATG9A	OTAZWZH7	Strong	Altered Expression	[128]
BAMBI	OTCEJ8W5	Strong	Altered Expression	[129]
BMP5	OTC0Y6E0	Strong	Altered Expression	[130]
CANX	OTYP1F6J	Strong	Biomarker	[131]
CAV2	OT1FGRQX	Strong	Altered Expression	[132]
CAV3	OTWSFDB4	Strong	Altered Expression	[132]
CBX4	OT4XVRRF	Strong	Genetic Variation	[133]
CCDC8	OTO295IH	Strong	Biomarker	[131]
CD177	OTS79FNF	Strong	Altered Expression	[134]
CD81	OTQFXNAZ	Strong	Genetic Variation	[135]
CD82	OTH8MC64	Strong	Altered Expression	[136]
CDC6	OTX93FE7	Strong	Altered Expression	[137]
CEP55	OTGSG2PA	Strong	Altered Expression	[138]
CIP2A	OTVS2GXA	Strong	Altered Expression	[139]
CLDN3	OT71MN9S	Strong	Altered Expression	[140]
CSTA	OT1K68KE	Strong	Biomarker	[141]
CTNND2	OTYKE30Y	Strong	Altered Expression	[142]
DYNLL1	OTR69LHT	Strong	Biomarker	[143]
EIF3H	OT61RBF5	Strong	Altered Expression	[144]
ELAC2	OTY3BOF6	Strong	Biomarker	[145]
ELL2	OTZJRTFM	Strong	Biomarker	[146]
ERG	OTOTX9VU	Strong	Biomarker	[87]
FGD4	OTYXJQCW	Strong	Altered Expression	[147]
FGF17	OTAQSFZ2	Strong	Altered Expression	[148]
FGL1	OTT0QHQ1	Strong	Altered Expression	[125]
FLVCR1	OT9XCFOC	Strong	Biomarker	[149]
FOXF1	OT2CJZ5K	Strong	Altered Expression	[150]
FOXF2	OTV20NGX	Strong	Altered Expression	[150]
FTL	OTYQA8A6	Strong	Altered Expression	[151]
FUZ	OTC427QQ	Strong	Altered Expression	[152]
FXYD3	OT9PPRHE	Strong	Altered Expression	[153]
GALNT3	OT7M67WT	Strong	Altered Expression	[154]
GATA6	OTO2BC0F	Strong	Altered Expression	[155]
GHRH	OT94U6MO	Strong	Biomarker	[156]
GIT1	OTHO92S5	Strong	Altered Expression	[38]
GLCE	OTPRSHX5	Strong	Altered Expression	[157]
GPC1	OTQKRSSV	Strong	Biomarker	[158]
GPRC5A	OTPOCWR7	Strong	Altered Expression	[82]
GRP	OT8JDFNI	Strong	Biomarker	[159]
GSTM3	OTLA2WJT	Strong	Genetic Variation	[160]
GTF2H2	OTK72L9I	Strong	Genetic Variation	[161]
HBS1L	OTA3U1N6	Strong	Altered Expression	[162]
HHEX	OTLIUVYX	Strong	Altered Expression	[163]
HNRNPM	OTFU3OEZ	Strong	Altered Expression	[164]
HOXC6	OTBCRAZV	Strong	Altered Expression	[31]
HPS1	OTKS5I7T	Strong	Altered Expression	[125]
HTRA2	OTC7616F	Strong	Altered Expression	[165]
IFI44	OTOKSZVA	Strong	Genetic Variation	[161]
IL10RA	OTOX3D1D	Strong	Genetic Variation	[53]
IL17RB	OT0KDNSF	Strong	Altered Expression	[166]
INSL3	OT7KUNTE	Strong	Altered Expression	[167]
IRX4	OT0TV6WK	Strong	Genetic Variation	[168]
ITGBL1	OTJDHE17	Strong	Altered Expression	[48]
KIDINS220	OTLBH2MA	Strong	Genetic Variation	[169]
KLK11	OT5PKX7Y	Strong	Altered Expression	[170]
KLK15	OT7BVG17	Strong	Altered Expression	[171]
KRT15	OTS6WLF7	Strong	Altered Expression	[48]
LEMD1	OTII3FTO	Strong	Altered Expression	[172]
LMLN	OTQF0JPY	Strong	Biomarker	[173]
MAGI2	OTXDDKZS	Strong	Biomarker	[174]
MARCHF5	OTBK6BBM	Strong	Genetic Variation	[29]
MED15	OT0D0JVD	Strong	Altered Expression	[82]
MEIS2	OTG4ADLM	Strong	Altered Expression	[175]
MZB1	OT071TET	Strong	Altered Expression	[13]
NAIP	OTLA925F	Strong	Altered Expression	[176]
NCOA1	OTLIUJQD	Strong	Biomarker	[177]
NDRG3	OTJTJCHD	Strong	Altered Expression	[178]
NFIB	OTX94PD0	Strong	Biomarker	[179]
NPRL2	OTOB10MO	Strong	Altered Expression	[180]
OR51E1	OTB7Q65H	Strong	Altered Expression	[181]
PAGE4	OT2VLWT0	Strong	Biomarker	[182]
PANK2	OTFBW889	Strong	Biomarker	[124]
PAQR3	OTTKJ9Y4	Strong	Posttranslational Modification	[183]
PIK3R3	OTXGJ8N1	Strong	Altered Expression	[184]
PLAG1	OTT9AJQY	Strong	Altered Expression	[70]
PLCL1	OTJL2C79	Strong	Biomarker	[185]
PLXNA1	OTN0BING	Strong	Biomarker	[186]
PMEPA1	OTY8Z9UF	Strong	Biomarker	[72]
PPP1R14A	OTQODWZB	Strong	Altered Expression	[155]
PRAC1	OT7MCG86	Strong	Biomarker	[187]
PRDX3	OTLB2WEU	Strong	Altered Expression	[188]
PRG2	OT0BCPQG	Strong	Biomarker	[189]
PRLH	OTJBP360	Strong	Altered Expression	[163]
PROS1	OTXQWNOI	Strong	Altered Expression	[70]
PSMG1	OTZ5I6UM	Strong	Biomarker	[190]
PTOV1	OT94WT5X	Strong	Altered Expression	[191]
PXN	OTVMMUOF	Strong	Altered Expression	[192]
PYCR1	OTQHB52T	Strong	Genetic Variation	[193]
QRFPR	OT31N14I	Strong	Altered Expression	[194]
RABGAP1L	OT7QO47I	Strong	Altered Expression	[195]
RANBP3L	OTKOCHVJ	Strong	Genetic Variation	[196]
RARRES1	OTETUPP5	Strong	Altered Expression	[82]
RASSF10	OTGB7EBG	Strong	Altered Expression	[197]
RFX6	OT8H77DL	Strong	Genetic Variation	[168]
RMC1	OT7K8MTJ	Strong	Altered Expression	[43]
RNF2	OTFPLOIN	Strong	Altered Expression	[198]
RPL10	OTBHOZGC	Strong	Biomarker	[186]
RPS10	OTE3VSAH	Strong	Biomarker	[199]
S100A2	OTTGHJ1H	Strong	Posttranslational Modification	[200]
SEMA3F	OTQFMS8S	Strong	Altered Expression	[201]
SETDB1	OTWVUA1B	Strong	Altered Expression	[202]
SFN	OTLJCZ1U	Strong	Biomarker	[82]
SMARCAL1	OTTKXLUZ	Strong	Biomarker	[124]
SOX11	OT4LG7LA	Strong	Posttranslational Modification	[203]
SPATA19	OT47CHQR	Strong	Altered Expression	[204]
SPOP	OTP0107S	Strong	Biomarker	[61]
SSBP2	OTYG1G80	Strong	Genetic Variation	[205]
STAG1	OT564IX4	Strong	Altered Expression	[72]
SULF1	OTJCNCO0	Strong	Altered Expression	[42]
TBC1D9	OTSSCTB5	Strong	Posttranslational Modification	[206]
TGM4	OTORRCG6	Strong	Altered Expression	[48]
TMEM45B	OTVQCO8N	Strong	Altered Expression	[207]
TMPRSS13	OTMAOAP3	Strong	Biomarker	[173]
TRPS1	OT7XPPEL	Strong	Altered Expression	[144]
TSPAN1	OTZQPIYK	Strong	Altered Expression	[208]
ANXA7	OTLMD0TK	Definitive	Biomarker	[209]
CDO1	OTLG1P77	Definitive	Biomarker	[210]
EFNA2	OTEAUKRX	Definitive	Biomarker	[211]
GUCA2B	OTZERX04	Definitive	Biomarker	[212]
IMMT	OTBDSLE7	Definitive	Biomarker	[213]
INHA	OT7HWCO3	Definitive	Altered Expression	[214]
NANOS2	OTFM2IDJ	Definitive	Altered Expression	[215]
NELL2	OTS4MJZ7	Definitive	Altered Expression	[216]
SIM2	OT0QWHK4	Definitive	Altered Expression	[217]
TPM1	OTD73X6R	Definitive	Altered Expression	[218]
------------------------------------------------------------------------------------


⏷ Show the Full List of 156 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7109).
2	Doxazosin FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7457).
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6818).
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 493).
7	Tadalafil FDA Label
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 488).
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7302).
10	ClinicalTrials.gov (NCT00090103) Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment. U.S. National Institutes of Health.
11	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
12	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022059)
13	PAC1-R null isoform expression in human prostate cancer tissue.Prostate. 2006 Apr 1;66(5):514-21. doi: 10.1002/pros.20356.
14	Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.Prostate. 2015 Aug 1;75(11):1197-205. doi: 10.1002/pros.23002. Epub 2015 Apr 15.
15	CGA gene (coding for the alpha subunit of glycoprotein hormones) overexpression in ER alpha-positive prostate tumors.Eur Urol. 2002 Mar;41(3):335-41. doi: 10.1016/s0302-2838(02)00020-9.
16	EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression.Oncotarget. 2015 Sep 8;6(26):22587-97. doi: 10.18632/oncotarget.4088.
17	Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.J Cancer Res Clin Oncol. 2014 Nov;140(11):1849-61. doi: 10.1007/s00432-014-1738-8. Epub 2014 Jun 18.
18	Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.Int J Cancer. 2014 Oct 1;135(7):1596-604. doi: 10.1002/ijc.28808. Epub 2014 Mar 4.
19	Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5--reductase.J Ethnopharmacol. 2019 May 10;235:65-74. doi: 10.1016/j.jep.2019.01.038. Epub 2019 Jan 29.
20	Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma.Andrology. 2020 Mar;8(2):427-433. doi: 10.1111/andr.12695. Epub 2019 Aug 21.
21	Molecular characterization of prostate hyperplasia in prolactin-transgenic mice by using cDNA representational difference analysis.Prostate. 2002 Jul 1;52(2):139-49. doi: 10.1002/pros.10102.
22	Detection of Loss of Heterozygosity (LOH) Using Circulating Cell-free DNA (cfDNA) by Fluorescence-based Multiplex PCR for Identification of Patients With Prostate Cancer.Appl Immunohistochem Mol Morphol. 2018 Nov/Dec;26(10):749-759. doi: 10.1097/PAI.0000000000000514.
23	TRPV6 alleles do not influence prostate cancer progression.BMC Cancer. 2009 Oct 26;9:380. doi: 10.1186/1471-2407-9-380.
24	Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.Medicine (Baltimore). 2016 Jul;95(29):e4326. doi: 10.1097/MD.0000000000004326.
25	Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.Nat Commun. 2018 Nov 8;9(1):4568. doi: 10.1038/s41467-018-06920-9.
26	Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1.Oncogene. 2018 Sep;37(39):5305-5324. doi: 10.1038/s41388-018-0294-0. Epub 2018 Jun 1.
27	Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia.Prostate. 2008 Jul 1;68(10):1064-75. doi: 10.1002/pros.20767.
28	Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.PLoS One. 2013 Jun 6;8(6):e60562. doi: 10.1371/journal.pone.0060562. Print 2013.
29	Meta-analysis of vitamin D receptor gene polymorphisms and benign prostatic hyperplasia risk.Mol Biol Rep. 2014 Oct;41(10):6713-7. doi: 10.1007/s11033-014-3554-2. Epub 2014 Jul 3.
30	The prognostic value of ADRA1 subfamily genes in gastric carcinoma.Oncol Lett. 2019 Sep;18(3):3150-3158. doi: 10.3892/ol.2019.10660. Epub 2019 Jul 24.
31	DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy.Br J Cancer. 2014 Aug 12;111(4):781-9. doi: 10.1038/bjc.2014.337. Epub 2014 Jun 17.
32	Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population?.Clin Genet. 2005 Jul;68(1):55-60. doi: 10.1111/j.1399-0004.2005.00450.x.
33	Identification of key genes and pathways in benign prostatic hyperplasia.J Cell Physiol. 2019 Nov;234(11):19942-19950. doi: 10.1002/jcp.28592. Epub 2019 Apr 4.
34	Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia.Genes Immun. 2012 Oct;13(7):566-72. doi: 10.1038/gene.2012.40. Epub 2012 Sep 6.
35	Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans.Biol Reprod. 1997 Jan;56(1):67-72. doi: 10.1095/biolreprod56.1.67.
36	The Obstructed Bladder: Expression of Collagen, Matrix Metalloproteinases, Muscarinic Receptors, and Angiogenic and Neurotrophic Factors in Patients With Benign Prostatic Hyperplasia.Urology. 2017 Aug;106:167-172. doi: 10.1016/j.urology.2017.05.010. Epub 2017 May 12.
37	Effects of Fungicide Propiconazole on the Yeast-Like Symbiotes in Brown Planthopper (BPH, Nilaparvata lugens Stl) and Its Role in Controlling BPH Infestation.Front Physiol. 2019 Feb 11;10:89. doi: 10.3389/fphys.2019.00089. eCollection 2019.
38	CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun. 2001 Apr 6;282(3):729-34.
39	Evidence for steroidogenic potential in human prostate cell lines and tissues.Am J Pathol. 2012 Sep;181(3):1078-87. doi: 10.1016/j.ajpath.2012.06.009. Epub 2012 Jul 13.
40	Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample.World J Urol. 2011 Apr;29(2):143-8. doi: 10.1007/s00345-009-0489-7. Epub 2009 Nov 17.
41	A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).BJU Int. 2018 Apr;121(4):647-658. doi: 10.1111/bju.14057. Epub 2017 Nov 16.
42	Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.J Cell Physiol. 2007 Jan;210(1):111-21. doi: 10.1002/jcp.20828.
43	Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation.Sci Rep. 2017 Dec 4;7(1):16824. doi: 10.1038/s41598-017-17207-2.
44	Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.Prostate. 2011 Apr;71(5):445-52. doi: 10.1002/pros.21258. Epub 2010 Sep 21.
45	The GnRH Antagonist Degarelix Directly Inhibits Benign Prostate Hyperplasia Cell Growth.Horm Metab Res. 2015 Nov;47(12):925-31. doi: 10.1055/s-0035-1555899. Epub 2015 Jul 21.
46	Role of GPR30 in estrogen-induced prostate epithelial apoptosis and benign prostatic hyperplasia.Biochem Biophys Res Commun. 2017 Jun 3;487(3):517-524. doi: 10.1016/j.bbrc.2017.04.047. Epub 2017 Apr 12.
47	Protective role of diosmin against testosterone propionate-induced prostatic hyperplasia in Wistar rats: Plausible role of oxidative stress and inflammation.Hum Exp Toxicol. 2020 Sep;39(9):1133-1146. doi: 10.1177/0960327119889655. Epub 2019 Dec 4.
48	Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies.Oncotarget. 2017 Nov 6;8(62):104761-104771. doi: 10.18632/oncotarget.22289. eCollection 2017 Dec 1.
49	Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.J Urol. 2004 Jan;171(1):187-91. doi: 10.1097/01.ju.0000101622.74236.94.
50	STX2171, a 17-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.Endocr Relat Cancer. 2013 Feb 18;20(1):53-64. doi: 10.1530/ERC-12-0231. Print 2013 Feb.
51	Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.World J Urol. 2017 Feb;35(2):293-298. doi: 10.1007/s00345-016-1869-4. Epub 2016 Jun 8.
52	Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.Endocrinology. 1999 May;140(5):2372-81. doi: 10.1210/endo.140.5.6702.
53	Association of IL10, IL10RA, and IL10RB polymorphisms with benign prostate hyperplasia in Korean population.J Korean Med Sci. 2011 May;26(5):659-64. doi: 10.3346/jkms.2011.26.5.659. Epub 2011 Apr 21.
54	Upregulated Interleukin 21 Receptor Enhances Proliferation and Epithelial-Mesenchymal Transition Process in Benign Prostatic Hyperplasia.Front Endocrinol (Lausanne). 2019 Jan 23;10:4. doi: 10.3389/fendo.2019.00004. eCollection 2019.
55	Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?.Exp Biol Med (Maywood). 2017 Dec;242(18):1795-1801. doi: 10.1177/1535370217728499. Epub 2017 Aug 24.
56	Genetic alterations and changes in expression of histone demethylases in prostate cancer.Prostate. 2010 Jun 1;70(8):889-98. doi: 10.1002/pros.21123.
57	Klotho inhibits androgen/androgen receptorassociated epithelialmesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.Oncol Rep. 2018 Jul;40(1):217-225. doi: 10.3892/or.2018.6399. Epub 2018 Apr 25.
58	Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia.Prostate. 2014 Jun;74(8):892-900. doi: 10.1002/pros.22807. Epub 2014 Apr 7.
59	Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.Prostate. 2011 Dec;71(16):1780-9. doi: 10.1002/pros.21395. Epub 2011 Apr 25.
60	Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker.Clin Chem. 2009 May;55(5):904-13. doi: 10.1373/clinchem.2008.103788. Epub 2009 Mar 19.
61	Potential Prognostic Role for SPOP, DAXX, RARRES1, and LAMP2 as an Autophagy Related Genes in Prostate Cancer.Urol J. 2020 Mar 16;17(2):156-163. doi: 10.22037/uj.v0i0.4935.
62	Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration.Oncotarget. 2014 Jun 30;5(12):4144-4153. doi: 10.18632/oncotarget.1928.
63	Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.Med Oncol. 2009;26(3):303-8. doi: 10.1007/s12032-008-9120-9. Epub 2008 Nov 12.
64	Association of LTR gene polymorphisms with prostate volume in benign prostatic hyperplasia in the Korean population.Genet Mol Res. 2015 Dec 29;14(4):18607-15. doi: 10.4238/2015.December.28.9.
65	Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its' effectiveness with botulinum toxin injection.Int Braz J Urol. 2017 Nov-Dec;43(6):1167-1175. doi: 10.1590/S1677-5538.IBJU.2016.0677.
66	MicroRNAs 143 and 145 may be involved in benign prostatic hyperplasia pathogenesis through regulation of target genes and proteins.Int J Biol Markers. 2014 Sep 30;29(3):e246-52. doi: 10.5301/jbm.5000069.
67	The prostate cancer-up-regulated Myc-associated zinc-finger protein (MAZ) modulates proliferation and metastasis through reciprocal regulation of androgen receptor.Med Oncol. 2013;30(2):570. doi: 10.1007/s12032-013-0570-3. Epub 2013 Apr 23.
68	Structural and molecular biology of PSP94: Its significance in prostate pathophysiology.Front Biosci (Landmark Ed). 2018 Jan 1;23(3):535-562. doi: 10.2741/4604.
69	Joint effects of inflammation and androgen metabolism on prostate cancer severity.Int J Cancer. 2008 Sep 15;123(6):1385-9. doi: 10.1002/ijc.23687.
70	TBL1Y: a new gene involved in syndromic hearing loss. Eur J Hum Genet. 2019 Mar;27(3):466-474. doi: 10.1038/s41431-018-0282-4. Epub 2018 Oct 19.
71	Ornithine decarboxylase (ODC) expression pattern in human prostate tissues and ODC transgenic mice.J Histochem Cytochem. 2006 Feb;54(2):223-9. doi: 10.1369/jhc.5A6672.2005. Epub 2005 Oct 18.
72	Prostate--specific G protein couple receptor genes and STAG1/PMEPA1 in peripheral blood from patients with prostatic cancer.Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):871-8. doi: 10.1177/039463200601900416.
73	Upregulation of Oxytocin Receptor in the Hyperplastic Prostate.Front Endocrinol (Lausanne). 2018 Aug 3;9:403. doi: 10.3389/fendo.2018.00403. eCollection 2018.
74	Activation of Prejunctional P2x2/3 Heterotrimers by ATP Enhances the Cholinergic Tone in Obstructed Human Urinary Bladders.J Pharmacol Exp Ther. 2020 Jan;372(1):63-72. doi: 10.1124/jpet.119.261610. Epub 2019 Oct 21.
75	The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.J Urol. 2009 Feb;181(2):594-600. doi: 10.1016/j.juro.2008.10.007. Epub 2008 Dec 13.
76	PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.Curr Cancer Drug Targets. 2014;14(2):105-14. doi: 10.2174/1568009613666131126113854.
77	The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.Prostate. 2013 Sep;73(13):1462-9. doi: 10.1002/pros.22693. Epub 2013 Jun 27.
78	Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.Br J Cancer. 2018 Jan;118(2):189-199. doi: 10.1038/bjc.2017.391. Epub 2017 Nov 14.
79	Implication of DNA repair genes in prostate tumourigenesis in Indian males.Indian J Med Res. 2012 Oct;136(4):622-32.
80	Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.Med Oncol. 2015 Mar;32(3):74. doi: 10.1007/s12032-015-0529-7. Epub 2015 Feb 20.
81	Regulatory network analysis of hypertension and hypotension microarray data from mouse model.Clin Exp Hypertens. 2018;40(7):631-636. doi: 10.1080/10641963.2017.1416120. Epub 2018 Feb 5.
82	Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing.Dis Markers. 2011;30(4):151-61. doi: 10.3233/DMA-2011-0790.
83	Autoantibodies Directed Against the Endothelin A Receptor in Patients With Benign Prostatic Hyperplasia.Prostate. 2017 Apr;77(5):458-465. doi: 10.1002/pros.23284. Epub 2016 Nov 24.
84	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression.Prostate. 2004 May 15;59(3):234-42. doi: 10.1002/pros.10361.
85	STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.Histopathology. 2013 Nov;63(5):678-85. doi: 10.1111/his.12226. Epub 2013 Sep 11.
86	Transforming growth factor-beta 3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma.Prostate. 1997 May 1;31(2):103-9. doi: 10.1002/(sici)1097-0045(19970501)31:2<103::aid-pros5>3.0.co;2-o.
87	Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia.Tumour Biol. 2014 Oct;35(10):9597-602. doi: 10.1007/s13277-014-2250-0. Epub 2014 Jun 25.
88	Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis.Lab Invest. 2004 Jun;84(6):785-95. doi: 10.1038/labinvest.3700075.
89	VPAC1 Targeted (64)Cu-TP3805 kit preparation and its evaluation.Nucl Med Biol. 2017 Aug;51:55-61. doi: 10.1016/j.nucmedbio.2017.04.007. Epub 2017 May 3.
90	Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia.Oncogene. 2000 Apr 27;19(18):2186-93. doi: 10.1038/sj.onc.1203561.
91	The Differential Expression and Function of the Inflammatory Chemokine Receptor CXCR5 in Benign Prostatic Hyperplasia and Prostate Cancer.Int J Med Sci. 2015 Oct 15;12(11):853-61. doi: 10.7150/ijms.11713. eCollection 2015.
92	Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.J Clin Endocrinol Metab. 2001 Apr;86(4):1700-6. doi: 10.1210/jcem.86.4.7413.
93	Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10.Endocr J. 1999 Jun;46(3):405-13. doi: 10.1507/endocrj.46.405.
94	Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.Asian J Androl. 2015 Jan-Feb;17(1):106-10. doi: 10.4103/1008-682X.137613.
95	Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.Hum Pathol. 2016 Jan;47(1):109-14. doi: 10.1016/j.humpath.2015.08.021. Epub 2015 Sep 28.
96	Uric acid: a modulator of prostate cells and activin sensitivity.Mol Cell Biochem. 2016 Mar;414(1-2):187-99. doi: 10.1007/s11010-016-2671-8. Epub 2016 Feb 24.
97	Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog.Mol Cell Endocrinol. 1995 Sep 22;113(2):195-204. doi: 10.1016/0303-7207(95)03630-p.
98	Expression of the non-gastric H+/K+ ATPase ATP12A in normal and pathological human prostate tissue.Cell Physiol Biochem. 2011;28(6):1287-94. doi: 10.1159/000335860. Epub 2011 Dec 16.
99	TREK-1 is a novel molecular target in prostate cancer.Cancer Res. 2008 Feb 15;68(4):1197-203. doi: 10.1158/0008-5472.CAN-07-5163.
100	VAT-1 is a novel pathogenic factor of progressive benign prostatic hyperplasia.Prostate. 2011 Oct 1;71(14):1579-86. doi: 10.1002/pros.21374. Epub 2011 Mar 10.
101	Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network.Sci Rep. 2019 Apr 15;9(1):6077. doi: 10.1038/s41598-019-42427-z.
102	Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia.Mol Biol Rep. 2013 Mar;40(3):2749-56. doi: 10.1007/s11033-012-2293-5. Epub 2012 Nov 27.
103	Expression of enzymes involved in estrogen metabolism in human prostate.J Histochem Cytochem. 2006 Aug;54(8):911-21. doi: 10.1369/jhc.6A6927.2006. Epub 2006 May 1.
104	Lack of association between the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and the risk of benign prostatic hyperplasia in Caucasian men.Mol Biol Rep. 2013 Dec;40(12):6665-9. doi: 10.1007/s11033-013-2781-2. Epub 2013 Sep 21.
105	Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.Gene. 2017 Nov 15;634:47-52. doi: 10.1016/j.gene.2017.08.038. Epub 2017 Sep 4.
106	Tumor-suppressive functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer.Cell Cycle. 2014;13(11):1798-810. doi: 10.4161/cc.28757. Epub 2014 Apr 14.
107	5-ARI induces autophagy of prostate epithelial cells through suppressing IGF-1 expression in prostate fibroblasts.Cell Prolif. 2019 May;52(3):e12590. doi: 10.1111/cpr.12590. Epub 2019 Mar 18.
108	The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer.Tumour Biol. 2015 Jan;36(1):329-35. doi: 10.1007/s13277-014-2642-1. Epub 2014 Sep 26.
109	DLEC1, a 3p tumor suppressor, represses NF-B signaling and is methylated in prostate cancer.J Mol Med (Berl). 2015 Jun;93(6):691-701. doi: 10.1007/s00109-015-1255-5. Epub 2015 Feb 5.
110	Mechanism of androgen receptor corepression by CKBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer.Mol Cell Endocrinol. 2014 Jan 25;382(1):302-313. doi: 10.1016/j.mce.2013.09.036. Epub 2013 Oct 5.
111	Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.Int J Oncol. 2014 Oct;45(4):1469-78. doi: 10.3892/ijo.2014.2545. Epub 2014 Jul 17.
112	Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance.J BUON. 2014 Jan-Mar;19(1):215-20.
113	BAP18 coactivates androgen receptor action and promotes prostate cancer progression.Nucleic Acids Res. 2016 Sep 30;44(17):8112-28. doi: 10.1093/nar/gkw472. Epub 2016 May 25.
114	Expression of leukemia/lymphoma related factor (LRF/Pokemon) in human benign prostate hyperplasia and prostate cancer.Exp Mol Pathol. 2011 Apr;90(2):226-30. doi: 10.1016/j.yexmp.2011.01.003. Epub 2011 Jan 18.
115	Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors.J Biol Chem. 2011 May 20;286(20):17796-808. doi: 10.1074/jbc.M110.198655. Epub 2011 Mar 17.
116	LILRA3 is associated with benign prostatic hyperplasia risk in a Chinese Population.Int J Mol Sci. 2013 Apr 24;14(5):8832-40. doi: 10.3390/ijms14058832.
117	High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.Prostate. 2012 Nov;72(15):1678-87. doi: 10.1002/pros.22521. Epub 2012 Apr 2.
118	SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer.Prostate. 2011 Oct 1;71(14):1559-67. doi: 10.1002/pros.21372. Epub 2011 Feb 25.
119	TM4SF1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration.Prostate. 2011 Aug 1;71(11):1239-50. doi: 10.1002/pros.21340. Epub 2011 Jan 12.
120	AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.J Clin Invest. 2007 Oct;117(10):2962-73. doi: 10.1172/JCI30710.
121	Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.Urology. 2011 Apr;77(4):1006.e1-7. doi: 10.1016/j.urology.2010.12.010. Epub 2011 Feb 18.
122	Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression.Int Urol Nephrol. 2018 Jan;50(1):35-47. doi: 10.1007/s11255-017-1743-3. Epub 2017 Nov 11.
123	anti-tumor effect of AlkB homolog 3 knockdown in hormone- independent prostate cancer cells.Curr Cancer Drug Targets. 2012 Sep;12(7):847-56. doi: 10.2174/156800912802429283.
124	Involvement of heparin affin regulatory peptide in human prostate cancer.Prostate. 1999 Feb 1;38(2):126-36. doi: 10.1002/(sici)1097-0045(19990201)38:2<126::aid-pros6>3.0.co;2-c.
125	Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.BJU Int. 2019 May;123(5A):E34-E42. doi: 10.1111/bju.14661. Epub 2019 Jan 27.
126	A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate.J Biol Chem. 2019 Aug 9;294(32):12231-12249. doi: 10.1074/jbc.RA119.007958. Epub 2019 Jun 26.
127	Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.PLoS One. 2011;6(10):e26595. doi: 10.1371/journal.pone.0026595. Epub 2011 Oct 20.
128	Deregulation of ATG9A by impaired AR signaling induces autophagy in prostate stromal fibroblasts and promotes BPH progression.Cell Death Dis. 2018 Apr 1;9(4):431. doi: 10.1038/s41419-018-0415-2.
129	Kangquan Recipe Regulates the Expression of BAMBI Protein via the TGF-/Smad Signaling Pathway to Inhibit Benign Prostatic Hyperplasia in Rats.Evid Based Complement Alternat Med. 2019 May 2;2019:6281819. doi: 10.1155/2019/6281819. eCollection 2019.
130	Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.JCI Insight. 2019 May 16;5(12):e129749. doi: 10.1172/jci.insight.129749.
131	Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.Prostate. 2005 May 15;63(3):252-8. doi: 10.1002/pros.20181.
132	NF-B and GATA-Binding Factor 6 Repress Transcription of Caveolins in Bladder Smooth Muscle Hypertrophy.Am J Pathol. 2019 Apr;189(4):847-867. doi: 10.1016/j.ajpath.2018.12.013. Epub 2019 Jan 30.
133	Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.Asian Pac J Cancer Prev. 2011;12(3):731-3.
134	Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines.J Urol. 1990 Jun;143(6):1272-4. doi: 10.1016/s0022-5347(17)40253-9.
135	Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.Prostate. 2019 May;79(6):592-603. doi: 10.1002/pros.23764. Epub 2019 Jan 24.
136	KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese.Asian J Androl. 2000 Sep;2(3):221-4.
137	CDC6 mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer.J Korean Med Sci. 2018 Nov 2;33(47):e303. doi: 10.3346/jkms.2018.33.e303. eCollection 2018 Nov 19.
138	Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.Immunobiology. 2015 Jan;220(1):103-8. doi: 10.1016/j.imbio.2014.08.014. Epub 2014 Aug 21.
139	CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.Tumour Biol. 2015 Jun;36(6):4777-83. doi: 10.1007/s13277-015-3129-4. Epub 2015 Jan 31.
140	Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.Mol Cell Proteomics. 2017 Jun;16(6):998-1008. doi: 10.1074/mcp.M117.068577. Epub 2017 Apr 9.
141	Characterization of prostate cancer in needle biopsy by cathepsin B, cell proliferation and DNA ploidy.Anticancer Res. 2010 Mar;30(3):719-25.
142	Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer.Int J Cancer. 2002 Jul 10;100(2):228-37. doi: 10.1002/ijc.10468.
143	Pathological patterns of prostate biopsy in men with fluctuations of prostate cancer gene 3 score: a preliminary report.Anticancer Res. 2015 Apr;35(4):2417-22.
144	Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.Br J Cancer. 2004 Mar 8;90(5):1041-6. doi: 10.1038/sj.bjc.6601648.
145	Polymorphisms in the HPC/ELAC-2 and alpha 1-antitrypsin genes that correlate with human diseases in a North Indian population.Mol Biol Rep. 2011 Jun;38(5):3137-44. doi: 10.1007/s11033-010-9984-6. Epub 2010 Feb 2.
146	Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia.J Endocrinol. 2017 Nov;235(2):123-136. doi: 10.1530/JOE-17-0112.
147	Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.BMC Cancer. 2018 Dec 17;18(1):1257. doi: 10.1186/s12885-018-5096-9.
148	FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.Prostate. 2004 Jun 15;60(1):18-24. doi: 10.1002/pros.20026.
149	Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer.Discov Med. 2019 Jun;27(150):235-243.
150	Gene expression of forkhead transcription factors in the normal and diseased human prostate.BJU Int. 2009 Jun;103(11):1574-80. doi: 10.1111/j.1464-410X.2009.08351.x. Epub 2009 Feb 11.
151	Association of ferritin with prostate cancer.J BUON. 2017 May-Jun;22(3):766-770.
152	Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.PLoS One. 2018 Jul 20;13(7):e0200613. doi: 10.1371/journal.pone.0200613. eCollection 2018.
153	External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes.Actas Urol Esp. 2015 Oct;39(8):473-81. doi: 10.1016/j.acuro.2015.02.002. Epub 2015 Apr 25.
154	Use of multiple biomarkers for a molecular diagnosis of prostate cancer.Int J Cancer. 2005 May 10;114(6):950-6. doi: 10.1002/ijc.20760.
155	GATA-6 and NF-B activate CPI-17 gene transcription and regulate Ca2+ sensitization of smooth muscle contraction.Mol Cell Biol. 2013 Mar;33(5):1085-102. doi: 10.1128/MCB.00626-12. Epub 2012 Dec 28.
156	P53, GHRH, inflammation and cancer.EBioMedicine. 2018 Nov;37:557-562. doi: 10.1016/j.ebiom.2018.10.034. Epub 2018 Oct 19.
157	Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer.Cancer Med. 2013 Oct;2(5):654-61. doi: 10.1002/cam4.108. Epub 2013 Aug 5.
158	Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.PLoS One. 2018 Apr 19;13(4):e0196017. doi: 10.1371/journal.pone.0196017. eCollection 2018.
159	Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging.Invest New Drugs. 2014 Feb;32(1):37-46. doi: 10.1007/s10637-013-9975-2. Epub 2013 Jun 1.
160	GSTM1, GSTM3 and GSTT1 gene variants and risk of benign prostate hyperplasia in North India.Dis Markers. 2009;26(2):85-91. doi: 10.3233/DMA-2009-0611.
161	Roles of the androgen receptor cofactor p44 in the growth of prostate epithelial cells.J Mol Endocrinol. 2006 Oct;37(2):283-300. doi: 10.1677/jme.1.02062.
162	Identification of reference genes and miRNAs for RT-qPCR in testosterone propionate-induced benign prostatic hyperplasia in rats.Andrologia. 2018 Feb 14. doi: 10.1111/and.12966. Online ahead of print.
163	CK2 abrogates the inhibitory effects of PRH/HHEX on prostate cancer cell migration and invasion and acts through PRH to control cell proliferation.Oncogenesis. 2017 Jan 30;6(1):e293. doi: 10.1038/oncsis.2016.82.
164	hnRNPM, a potential mediator of YY1 in promotingthe epithelial-mesenchymal transition of prostate cancer cells.Prostate. 2019 Aug;79(11):1199-1210. doi: 10.1002/pros.23790.
165	Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.APMIS. 2006 Dec;114(12):893-8. doi: 10.1111/j.1600-0463.2006.apm_271.x.
166	Stromal factors involved in human prostate cancer development, progression and castration resistance.J Cancer Res Clin Oncol. 2017 Feb;143(2):351-359. doi: 10.1007/s00432-016-2284-3. Epub 2016 Oct 27.
167	INSL3 in the benign hyperplastic and neoplastic human prostate gland. Int J Oncol. 2005 Aug;27(2):307-15.
168	Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population.Prostate. 2013 Aug;73(11):1182-90. doi: 10.1002/pros.22666. Epub 2013 Apr 26.
169	HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population.Gene. 2017 May 20;613:20-24. doi: 10.1016/j.gene.2017.02.031. Epub 2017 Mar 1.
170	mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy.Biol Chem. 2006 Jun;387(6):789-93. doi: 10.1515/BC.2006.099.
171	Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.Cancer Sci. 2010 Mar;101(3):693-9. doi: 10.1111/j.1349-7006.2009.01450.x. Epub 2009 Nov 27.
172	Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer.Arch Med Res. 2010 Apr;41(3):195-200. doi: 10.1016/j.arcmed.2010.04.003.
173	SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.Gene. 2016 Nov 30;593(2):292-301. doi: 10.1016/j.gene.2016.08.030. Epub 2016 Aug 26.
174	MAGI-2 in prostate cancer: an immunohistochemical study.Hum Pathol. 2016 Jun;52:83-91. doi: 10.1016/j.humpath.2016.01.003. Epub 2016 Feb 4.
175	Epigenetic silencing of MEIS2 in prostate cancer recurrence.Clin Epigenetics. 2019 Oct 22;11(1):147. doi: 10.1186/s13148-019-0742-x.
176	Survivin and NAIP in Human Benign Prostatic Hyperplasia: Protective Role of the Association of Serenoa repens, Lycopene and Selenium from the Randomized Clinical Study.Int J Mol Sci. 2017 Mar 22;18(3):680. doi: 10.3390/ijms18030680.
177	Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro.Front Pharmacol. 2018 Jul 16;9:773. doi: 10.3389/fphar.2018.00773. eCollection 2018.
178	NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth.Int J Cancer. 2009 Feb 1;124(3):521-30. doi: 10.1002/ijc.23961.
179	Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.Endocrinology. 2016 Mar;157(3):1094-109. doi: 10.1210/en.2015-1312. Epub 2015 Dec 17.
180	NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.Prostate. 2019 Jan;79(1):44-53. doi: 10.1002/pros.23709. Epub 2018 Sep 3.
181	PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer.Int J Cancer. 2006 Mar 15;118(6):1471-80. doi: 10.1002/ijc.21527.
182	Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation.Mech Ageing Dev. 2005 Jan;126(1):59-69. doi: 10.1016/j.mad.2004.09.023.
183	Aberrant promoter methylation of the PAQR3 gene is associated with prostate cancer.Pathol Res Pract. 2018 Jan;214(1):126-129. doi: 10.1016/j.prp.2017.10.010. Epub 2017 Oct 10.
184	piRNA-DQ722010 contributes to prostate hyperplasia of the male offspring mice after the maternal exposed to microcystin-leucine arginine.Prostate. 2019 May;79(7):798-812. doi: 10.1002/pros.23786. Epub 2019 Mar 22.
185	Combination of phospholipase C knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.Oncol Rep. 2019 May;41(5):2689-2702. doi: 10.3892/or.2019.7054. Epub 2019 Mar 7.
186	Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues.Mol Pathol. 2001 Aug;54(4):275-80. doi: 10.1136/mp.54.4.275.
187	Aberrant expression of the PRAC gene in prostate cancer.Int J Oncol. 2013 Dec;43(6):1960-6. doi: 10.3892/ijo.2013.2117. Epub 2013 Oct 2.
188	Mitochondrion-associated protein peroxiredoxin 3 promotes benign prostatic hyperplasia through autophagy suppression and pyroptosis activation.Oncotarget. 2017 May 17;8(46):80295-80302. doi: 10.18632/oncotarget.17927. eCollection 2017 Oct 6.
189	Upregulation of SPOCK2 inhibits the invasion and migration of prostate cancer cells by regulating the MT1-MMP/MMP2 pathway.PeerJ. 2019 Jul 12;7:e7163. doi: 10.7717/peerj.7163. eCollection 2019.
190	PACAP and type I PACAP receptors in human prostate cancer tissue.Ann N Y Acad Sci. 2006 Jul;1070:440-9. doi: 10.1196/annals.1317.059.
191	PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks.Oncogene. 2001 Mar 22;20(12):1455-64. doi: 10.1038/sj.onc.1204233.
192	Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence.J Cancer. 2018 Feb 28;9(6):959-967. doi: 10.7150/jca.22787. eCollection 2018.
193	MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.Carcinogenesis. 2007 Dec;28(12):2530-6. doi: 10.1093/carcin/bgm196. Epub 2007 Sep 3.
194	Involvement of the glutamine RFamide peptide and its cognate receptor GPR103 in prostate cancer.Oncol Rep. 2019 Feb;41(2):1140-1150. doi: 10.3892/or.2018.6893. Epub 2018 Nov 27.
195	Tissue ACE phenotyping in prostate cancer.Oncotarget. 2019 Oct 29;10(59):6349-6361. doi: 10.18632/oncotarget.27276. eCollection 2019 Oct 29.
196	Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the -adrenergic receptor antagonist.Aging Male. 2017 Dec;20(4):250-256. doi: 10.1080/13685538.2017.1358261. Epub 2017 Aug 8.
197	Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.Prostate. 2012 Oct 1;72(14):1550-8. doi: 10.1002/pros.22510. Epub 2012 Mar 13.
198	Knockdown of RNF2 induces cell cycle arrest and apoptosis in prostate cancer cells through the upregulation of TXNIP.Oncotarget. 2017 Jan 17;8(3):5323-5338. doi: 10.18632/oncotarget.14142.
199	The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.Proteomics. 2016 Apr;16(8):1204-14. doi: 10.1002/pmic.201500378. Epub 2016 Apr 4.
200	Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.Prostate. 2005 Dec 1;65(4):322-30. doi: 10.1002/pros.20302.
201	SSeCKS/AKAP12 induces repulsion between human prostate cancer and microvessel endothelial cells through the activation of Semaphorin 3F.Biochem Biophys Res Commun. 2017 Sep 2;490(4):1394-1398. doi: 10.1016/j.bbrc.2017.07.043. Epub 2017 Jul 8.
202	Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.Asian J Androl. 2014 Mar-Apr;16(2):319-24. doi: 10.4103/1008-682X.122812.
203	Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer.Int J Exp Pathol. 2017 Dec;98(6):341-346. doi: 10.1111/iep.12257. Epub 2018 Jan 8.
204	Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.APMIS. 2017 Dec;125(12):1092-1101. doi: 10.1111/apm.12775. Epub 2017 Oct 3.
205	ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer.Clin Cancer Res. 2008 Jun 15;14(12):3754-60. doi: 10.1158/1078-0432.CCR-07-4763.
206	Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.BMC Genomics. 2013 Dec 17;14:898. doi: 10.1186/1471-2164-14-898.
207	TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis.Neoplasma. 2018 Sep 19;65(5):815-821. doi: 10.4149/neo_2018_170822N551. Epub 2018 Sep 4.
208	The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration.Sci Rep. 2017 Jul 12;7(1):5249. doi: 10.1038/s41598-017-05489-5.
209	ANX7 as a bio-marker in prostate and breast cancer progression.Dis Markers. 2001;17(2):115-20. doi: 10.1155/2001/239602.
210	CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.Epigenetics. 2016 Dec;11(12):871-880. doi: 10.1080/15592294.2016.1241931. Epub 2016 Sep 30.
211	Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.Tumour Biol. 2016 Apr;37(4):5365-74. doi: 10.1007/s13277-015-4398-7. Epub 2015 Nov 11.
212	Occurrence and localization of uroguanylin in the aging human prostate.Histochem Cell Biol. 2003 Jan;119(1):69-76. doi: 10.1007/s00418-002-0490-3. Epub 2002 Dec 21.
213	Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression.J Cell Physiol. 2016 Jun;231(6):1364-74. doi: 10.1002/jcp.25240. Epub 2015 Nov 24.
214	Loss of the expression and localization of inhibin alpha-subunit in high grade prostate cancer.J Clin Endocrinol Metab. 1998 Mar;83(3):969-75. doi: 10.1210/jcem.83.3.4640.
215	Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology.J Pathol. 1999 Oct;189(2):224-9. doi: 10.1002/(SICI)1096-9896(199910)189:2<224::AID-PATH422>3.0.CO;2-K.
216	Identification of genes differentially expressed in benign prostatic hyperplasia.J Histochem Cytochem. 2001 May;49(5):669-70. doi: 10.1177/002215540104900517.
217	Down's syndrome-associated single minded gene as a novel tumor marker.Anticancer Res. 2002 Nov-Dec;22(6A):3149-57.
218	Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array.J Pathol. 2001 Jan;193(1):73-9. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH751>3.0.CO;2-Y.